Remove Cardio Oncology Remove Cardiovascular Disease Remove Obesity
article thumbnail

Highlights of ACC 2024

Cardiology Update

Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovascular disease (CVD). STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes.

Angina 52